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It was recently shown that mouse fibroblasts could
be reprogrammed into cells of a cardiac fate by
forced expression of multiple transcription factors
andmicroRNAs. For ultimate application of such a re-
programmingstrategy for cell-based therapyor invivo
cardiac regeneration, reducing or eliminating the
genetic manipulations by small molecules would be
highly desirable. Here, we report the identification of
a defined small-molecule cocktail that enables the
highly efficient conversion of mouse fibroblasts into
cardiac cells with only one transcription factor, Oct4,
without any evidence of entrance into the pluripotent
state.Small-molecule-inducedcardiomyocytesspon-
taneously contract and exhibit a ventricular pheno-
type. Furthermore, these induced cardiomyocytes
pass through a cardiac progenitor stage. This study
lays the foundation for futurepharmacological reprog-
ramming approaches and provides a small-molecule
condition for investigation of the mechanisms under-
lying the cardiac reprogramming process.
INTRODUCTION
Heart failure, a leading cause of mortality, typically results in the
loss or dysfunction of cardiomyocytes (Kathiresan and Srivas-
tava, 2012). Despite biomedical advances to prevent or limit car-
diovascular disease, restoring the function of a damaged heart
is a formidable challenge. This is in part attributed to the limited
regenerative capability of adult cardiomyocytes. However, the
human heart also contains a large population of endogenous
cardiac fibroblasts (Ieda et al., 2009) that could serve as a cell
source for regenerative therapy if they could be directly re-
programmed into beating cardiomyocytes. Recent advances in
induced pluripotent stem cell (iPSC) technology have regalvan-
ized research on reprogramming of one somatic cell type intoanother developmentally nonpermissive cell type without pass-
ing through the pluripotent state, a process known as transdiffer-
entiation (Sancho-Martinez et al., 2012). This approach offers
promise that the repair of damaged hearts can be achieved
with reduced risk of tumorigenesis associated with pluripotent
cells via cell-replacement therapy and/or in vivo regeneration
by cellular reprogramming.
In addition to the conventional paradigm of using target
cell-type-specific factors (e.g., transcription factors [TFs] and
microRNAs) for transdifferentiation, we previously established
the cell-activation and signaling-directed (CASD) lineage
conversion method. This approach employs transient over-
expression of iPSC-TFs (cell activation) in conjunction with
lineage-specific soluble signals (signal directed) to reprogram
somatic cells into diverse lineage-specific cell types without
entering thepluripotent state.Using this approach,weandothers
have reported the generation of induced cardiac (Efe et al., 2011),
neural (Han et al., 2012; Kim et al., 2011; Lu et al., 2013; Thier
et al., 2012; Zhu et al., 2014), and endothelial cells (Li et al.,
2013) and definitive endoderm (Li et al., 2014) from mouse and
human fibroblasts without first establishing the pluripotent state.
Although the above approaches employing multiple (e.g.,
three to seven) genetic factors established proof of concept to
reprogram noncardiac cells to cardiomyocyte-like cells (Ieda
et al., 2010; Qian et al., 2012; Song et al., 2012), such genetic
manipulations inevitably harbor safety, efficiency, and other
technical issues. Alternatively, to more effectively apply trans-
differentiation to cell-based therapies and/or in vivo repair/
regeneration of endogenous cells in an ultimately tissue-specific
manner, it would be essential to develop methods that eliminate
or reduce the dependence on genetic manipulation. Replacing
the cardiac reprogramming TFs with defined small molecules
would therefore represent an essential first step toward the
ultimate pharmacological induction of cardiac cells. Such small
molecules may also enhance reprogramming for in vitro applica-
tions and provide chemical tools to study the underlying reprog-
ramming mechanisms.
Toward this end, we screened for small-molecule conditions
that can replace TFs to reprogrammouse fibroblasts into cardiacCell Reports 6, 951–960, March 13, 2014 ª2014 The Authors 951
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cells. Because the general CASD lineage-conversion process
depends on only transient iPSC-TF expression and not on the
establishment of pluripotency (Efe et al., 2011; Kim et al.,
2011), we hypothesized that ectopic expression of TFs might
be more easily substituted by small molecules known to induce
or enhance iPSC generation. Here, we report the identification
of a defined small-molecule cocktail consisting of SB431542
(ALK4/5/7 inhibitor), CHIR99021 (GSK3 inhibitor), parnate
(LSD1/KDM1 inhibitor, also called tranylcypromine), and forsko-
lin (adenylyl cyclase activator). This cocktail enabled the con-
version of mouse fibroblasts into cardiomyocytes with only one
TF, Oct4, without traversing the pluripotent state. Small-mole-
cule-enabled cardiac reprogramming is very efficient, inducing
the conversion of fibroblasts to spontaneously beating cardio-
myocytes that exhibit a ventricular phenotype while drastically
reducing the number of genetic reprogramming factors required
(i.e., from four TFs to one TF). This study lays the foundation for
developing methods for 100% pharmacological reprogramming
and provides a small-molecule condition for investigation of the
mechanisms underlying lineage reprogramming.
RESULTS
Small-Molecule Cocktails Enable the Cardiac
Conversion of Mouse Fibroblasts in Conjunction with a
Single Transcription Factor, Oct4
To develop small-molecule conditions for inducing cardiac re-
programming from mouse fibroblasts, we envisioned a strategy
based on the CASD paradigm that combines iPSC-inducing
and iPSC-enhancing small molecules to induce cell activation
with cardiogenic small molecules that serve to direct the cardio-
myocyte fate. In previous studies,we and others identified a large
number of small molecules that, either alone or in combination,
enhance reprogramming efficiency and/or accelerate reprog-
ramming speed (Nie et al., 2012; Zhu et al., 2011). Importantly,
some combinations can functionally substitute one, two, or three
reprogramming TFs to generate iPSCs from various mouse and
human somatic cell types (Li et al., 2009, 2011; Shi et al., 2008;
Yuan et al., 2011; Zhu et al., 2010). Those smallmolecules include
modulators of epigenetic enzymes, signaling pathways, meta-
bolism, and transcription. In recent years, cardiogenic small mol-
ecules were also identified in studies of the pluripotent stem cell
differentiation process, including modulators of the Wnt, trans-
forminggrowth factorb (TGF-b), BMP,andactivin/nodal signaling
pathways (Hilcove, 2010; Kattman et al., 2011; Lian et al., 2012;
Naito et al., 2006; Willems et al., 2012; Yang et al., 2008).
In the present study, we first tested small molecules in the
presence of three TFs (Oct4, Klf4, and Sox2/OKS) to determineFigure 1. The Small-Molecule Cocktail, SCPF, Enables Cardiac Reprog
(A) The scheme of direct cardiac reprogramming with the small-molecule cockta
(B) Immunostaining of cTnT and cardiac MHC in beating clusters generated from
(C) Quantitative PCR analysis of indicated markers in the induced cardiomyocytes
were used as negative or positive controls.
(D and E) Immunostaining of various markers in small clumps or single cells dige
(F) Chromatin immunoprecipitation assays examining H3K4me3 and H3K27me3
neonatal heart tissues (‘‘H’’). Quantitative PCR was used to assess changes in H
100 mm.which combinations mediated efficient cardiac reprogramming.
To better control exogenous TF expression and minimize
variability in screening, we used a lentiviral construct carrying
the three TFs/OKS in a single tetracycline-inducible vector
(pHAGE2-TetO-STEMCCA-redlight, or TetO-OKS). To carry
out the screening, mouse embryonic fibroblasts (MEFs) were
infected with TetO-OKS and split into 24-well plates. The various
small-molecule combinations and doxycycline (Dox) were added
into the cardiac reprogramming medium (CRM; see Experi-
mental Procedures) for the first 6 days and were followed by
treatment with BMP4. The number of beating cell clusters was
counted as a readout of reprogramming efficiency (Figure S1A).
In control wells without any compound treatment, there were few
beating clusters, whereas the single addition of SB431542 or
CHIR99021 slightly increased reprogramming efficiency. How-
ever, exposure to both SB431542 and CHIR99021 doubled the
efficiency of cardiac reprogramming. Owing to the synergism
induced by Wnt signaling activation and TGF-b signaling inhibi-
tion, the combination of SB431542 and CHIR99021 (SC) became
our baseline small-molecule condition in conjunction with TFs,
on top of which additional iPSC inducing/enhancing and cardio-
genic small molecules were screened. Primary hits that could
enhance cardiac reprogramming under the basal condition con-
taining CHIR99021 and SB431542 are shown in Figure S1B and
Table S1. Different small-molecule combinations were then
further tested and optimized. Notably, we found that the addition
of parnate (LSD1/KDM1 inhibitor) and forskolin (adenylyl cyclase
activator) together further increased the reprogramming effi-
ciency dramatically. This result was confirmed in a larger-well
format as shown in Figures S1C and S1D. Hereafter, the small-
molecule combination of SB431542, CHIR99021, parnate, and
forskolin will be referred to as SCPF.
With this remarkable efficiency of cardiac induction, we next
asked whether SCPF could enable cardiac reprogramming in
conjunction with a single TF, Oct4. We found that MEFs infected
with Oct4 and treated with SCPF could indeed be converted
to spontaneously contracting clusters (Figure 1A). The first con-
tracting cluster was observed around day 20. At day 30, a total
of 99 ± 17 contracting clusters could be generated from the
original 10,000 plated MEFs (n = 6). In contrast, no beating clus-
ters were found in control wells without compound treatment.
Immunocytochemistry analysis confirmed that these beating
patches were positive for cardiac-specific markers, including
cardiac troponin-T (cTnT) and cardiac myosin heavy chain
(cMHC) (Figure 1B).
To exclude the possibility that beating cells might be gener-
ated from rare cardiac progenitors in MEF cells, we next tested
whether, in conjunction with Oct4, SCPF could enable cardiacramming with a Single Factor, Oct4
il, SCPF, and a single factor, Oct4.
MEFs at day 25.
(iCM) from TTFs at day 35. mRNA from TTFs and neonatal heart (in short, ‘‘H’’)
sted from TTF-derived beating clusters. Scale bar is 100 mm.
at three cardiac loci during reprogramming at day 0 (D0), day 40 (D40), and
3K4me3 (left) and H3K27me3 (right) levels. Data are mean ± SD. Scale bars,
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induction in mouse tail-tip fibroblasts (TTFs), a much more
homogenous cell population that does not contain any cardiac
lineage cells. Using the same conditions applied to MEFs (Fig-
ure 1A), we found that nearly 50 spontaneously beating colonies
(n = 6) could be generated from 10,000 TTFs by day 30. Quanti-
tative RT-PCR (qRT-PCR) showed that cardiac-specific genes,
including Myh6, Tnnt2, Ryr2, Gata4, and Nkx2-5, were highly
expressed in these induced cardiomyocytes compared with
control TTFs (Figure 1C). To further characterize these reprog-
rammed TTFs, large beating patches of cells were digested
into small cell clusters or single cells for immunocytochemistry
analysis. These induced cardiomyocytes displayed a tri- or mul-
tiangular morphology. Immunocytochemistry analysis revealed
that these cells were positive for the cardiomyocyte markers
cTnT and a-actinin and displayed a clear cross-striated pattern
(Figure 1D). Core TFs and peptides important for cardiac devel-
opment and function, including Gata4, Mef2c, and Nkx2-5, as
well as ANP, were also highly expressed in the induced cardio-
myocytes. Moreover, connexin-43 (Cx43), a gap junction protein
expressed in cardiomyocytes, was also detected along the
periphery of the induced cardiomyocytes, indicating the devel-
opment of gap junctions for intercellular communication (Fig-
ure 1E). To investigate relevant epigenetic changes, we used
chromatin immunoprecipitation quantitative PCR assays to
examine H3K4me3 and H3K27me3 at three key cardiac loci:
Actn2 (encoding a-actinin), Ryr2 (encoding the cardiac ryano-
dine receptor), and Tnnt2 (encoding cardiac troponin T). As
shown in Figure 1F, we observed that the promoters of these
three cardiac genes exhibited increased H3K4me3 and
decreased H3K27me3 compared to initial MEFs (D0), consistent
with cardiac reprogramming and gene expression.
Serendipitously, we also consistently observed a few twitch-
ing/contracting cells in the control wells treated only with small
molecules (e.g., SCPF) without Oct4 transduction. They ex-
hibited a long tube-like morphology different from neonatal
cardiomyocytes, pluripotent stem cell-derived cardiomyocytes,
or induced cardiomyocytes obtained in the presence of Oct4
and characterized above. Interestingly, they were positive for
cTnT, cMHC, and a-actinin immunostaining (Figure S2A). How-
ever, further characterization revealed that core cardiac TFs,
such as Nkx2-5 and Gata4, were barely detected in those
cells (Figure S2B), whereas they modestly expressed skeletal
muscle TFs like MyoD and myogenin (Figure S2C). These find-
ings suggest that these tube-like contracting cells are not fully
reprogrammed cardiomyocytes or may instead possess certain
skeletal muscle features. Therefore, we did not further investi-
gate them in this study.
Induced Cardiomyocytes Exhibited Typical Cardiac
Electrophysiological Features
We next sought to characterize the functional properties of these
TTF-derived induced cardiomyocytes by electrophysiological
analysis. Using a single-cell patch-clamp technique, action po-
tentials (APs) were recorded from single spontaneously beating
cells around day 35 of reprogramming. Based on the ratio of
AP duration at 90% repolarization (APD90) to APD50 (Kuzmenkin
et al., 2009), we found that most of our induced cardiomyocytes
showed ventricular-like AP morphology with a mean diastolic954 Cell Reports 6, 951–960, March 13, 2014 ª2014 The Authorspotential (MDP) of 75.2 mV and a mean overshoot potential
(OSP) of 23.5mV (n = 16), whereas very few of the cells displayed
atrial or nodal-like APs (Figures 2A and 2B). Consistently, immu-
nostaining analysis confirmed expression of myosin light chain-
2v (MLC2v), a ventricular-specific marker, in most of the induced
cardiomyocytes (Figure 2C). This is in contrast to our previous
four-factor (OSKM) cardiac reprogramming condition, where
only atrial-like APswere detected in the induced cardiomyocytes
(Efe et al., 2011). This finding suggests that subtype specificity of
induced cardiomyocytes can be modulated by small-molecule
conditions. Consequently, the newly developed SCPF/Oct4
condition may represent a more desirable condition for cardiac
reprogramming, becuase ventricular cardiomyocytes are typi-
cally lost in heart failure. In addition, the maximal depolarization
rate (Vmax) for ventricular-like APs was comparatively very high
(Kuzmenkin et al., 2009), which is likely accounted for by a com-
bination of the appreciable density of tetrodotoxin (TTX)-sensi-
tive Na current (185 ± 32 A/F, n = 9 cells; Figure S3) and the
relatively hyperpolarized MDP. In conclusion, these data confirm
that cardiomyocytes induced by SCPF/Oct4 possess many
typical cardiac electrophysiological features. Moreover, typical
Ca2+ transients, which underlie the contraction and relaxation
of spontaneously beating cardiomyocytes, were also detected
(Figure 2D). The peak fluorescence ratio in these transients
(i.e., peak fluorescence expressed relative to the resting level
[F/Fo]) was 2.72 ± 0.22 (n = 5) and is comparable to previous
measurements made using embryonic or embryonic stem cell-
derived myocytes (Korhonen et al., 2010; Lieu et al., 2009; Sauer
et al., 2001). Calibrated intracellular free [Ca2+] peaked at 320 ±
30 nM (n = 5), which is also consistent with previous estimates
from intact ventricular myocytes (Takamatsu et al., 2003)
indicating the development of functional excitation-contraction
coupling in these cells.
The ability to respond appropriately to hormones and trans-
mitters of the autonomic nervous system is among the most crit-
ical functions of normal cardiomyocytes. We therefore sought
to determine how TTF-derived induced cardiomyocytes respond
to b-adrenergic and muscarinic stimulation. Addition of the
b-adrenergic agonist isoproterenol (Iso) significantly increased
the frequency of cell contractions and spontaneous calcium
transients (Figures 2E and 2F), whereas carbachol (CCh), a
muscarinic agonist, had the opposite effect (Figures 2G and
2H). After washing out carbachol, cells immediately resumed
contracting at baseline frequency (Figure 2H). The reversible
modulation of the frequency of Ca2+ transients by Iso or CCh in-
dicates that coupled b-adrenergic and muscarinic signaling cas-
cades, as well as their associated intracellular signaling partners,
are present and functional.
Induced Cardiomyocytes Were Generated through
Cardiac Precursor Stage
As shown in Figure S1C and Figure 1B, we found that the beating
clusters were clonally derived. Next, we examined whether
induced cardiomyocytes were generated through a cardiac pre-
cursor stage. Consistent with previous findings, robust expres-
sion of Flk1, Mesp1, Isl1, and Gata4, all of which are widely
used as cardiac progenitor markers, could be detected during
the early cardiac reprogramming stage by qRT-PCR (Figure 3A).
Figure 2. Contracting Cardiomyocytes Generated by SCPF/Oct4 Exhibit Typical Electrophysiological Features
TTFs were converted into spontaneously contracting cardiomyocytes by SCPF/Oct4. Spontaneous action potentials (APs) and calcium transients were recorded
from the individual cardiomyocytes at day 35–40.
(A) Representative spontaneous APs showing characteristics of ventricular or atrial-like morphology. The waveform of a single AP is shown on the right using an
expanded timescale. Dotted lines indicate zero membrane potential (0 mV).
(B) Table of AP parameters measured for the induced cardiomyocytes, including maximum upstroke velocity (dV/dt max), overshoot potential (OSP), minimum
diastolic potential (MDP), AP amplitude, AP durations (APDs) at the level of 90% and 50% repolarization, and the beating frequency. Data are mean ± SEM.
Significance levels are symbolized (*p < 0.005, **p < 0.001).
(C) Triple immunostaining of cTnT, MLC2v, and MLC2a antibody on induced cardiomyocytes at day 45. Scale bars, 100 mm.
(D) Characteristic calcium transients ([Ca2+]i) recorded from the spontaneously contracting cardiomyocytes generated by SCPF/Oct4.
(E–H) Record of calcium transients showing the effects on beating rates of treatment with 1 mM isoproterenol (Iso) (E and F) and 25 mMcarbachol (CCh) (G and H).
Data are mean ± SD.
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Importantly, the Isl1-positive cells were also found to be Ki-67
positive by immunostaining (Figure 3B), indicating that those
cells are mitotically active precursor cells. During embryonic
development, cardiac precursors also differentiate into smooth
muscle cells and endothelial cells. Consistently, after BMP4
treatment, when we switched to different cell-differentiation
conditions that favor either endothelial or smooth muscle cell
differentiation and maintenance, endothelial or smooth muscle
cells could be generated, respectively (Figures 3C and 3D).
Gene expression analysis of smooth muscle cell markers,
including ATCA2,Myh11, and calponin 2 (Cnn2), and endothelial
cell markers, including CD146, VE-cadherin, CD31, and Tie1,
by qRT-PCR further confirmed the generation of those cardio-
vascular cell types (Figures 3E and 3F). These results suggest
the generation of nascent cardiac precursors during a critical
reprogramming window. To further confirm this, we conducted
a lineage tracing study using sorted GFP-negative Isl1-Cre/
ROSAmTmG MEFs (which would mark Isl1-expressing cells
permanently with GFP) (Muzumdar et al., 2007; Srinivas et al.,
2001), which were induced to beating cardiomyocytes under
the same reprogramming condition. It was found that GFP-pos-
itive cells were generated after the addition of BMP4 (Figure 3G)
and then they became beating clusters (Figure 3H; Movie S1).
All these results collectively indicate that induced cardiomyo-
cytes generated by our method have passed through a cardiac
precursor stage.
The Pluripotent State Was Not Established during the
Reprogramming of Fibroblasts to Cardiomyocyte-like
Cells
The reprogramming of adult cells to iPSCs generally depends on
the presence of LIF. Although LIF is not added to our transdiffer-
entiation cocktail, we nevertheless wanted to rule out the possi-
bility that our reprogramming paradigm induces iPSCs en route
to cardiomyocytes. Therefore, to more carefully examine the
reprogramming process, we performed time-lapse imaging
of OG2 MEFs (Oct4-GFP reporter-expressing MEFs) (Do and
Scho¨ler, 2004) undergoing SCPF/Oct4-induced cardiac reprog-
ramming (Figures 4A and 4B). Using OG2MEFs, the presence of
iPSCs can be clearly detected by GFP fluorescence (Figure 4C).
We observed the first beating cluster at day 20 of a 25-day
imaging period, and immunohistochemistry analysis confirmed
that those beating clusters were cTnT positive (Figure 4B; Movie
S2). However, GFP+ cells were never detected throughout the
whole reprogramming process (Figure 4A). This finding is consis-
tent with our previous studies on direct cardiac, neural and endo-
thelial cell reprogramming using the CASD paradigm (Efe et al.,
2011; Kim et al., 2011; Li et al., 2013). By qRT-PCR, the expres-Figure 3. Induced Cardiomyocytes Were Generated through the Cardi
(A) Time course analysis of cardiac precursor marker expression by quantitative R
embryonic day 13.5.
(B) At day 20, cells were fixed and immunostained with Isl1 and Ki-67 antibodies
(C–F) After BMP4 treatment, culturemediumwas switched to either smoothmusc
(D and F) for another 2 weeks. Cells were then fixed and stained with smooth
antibodies (D). mRNA expression of indicated markers were analyzed by quantit
(G and H) MEFs from Isl1-Cre/ROSAmTmG were used for cardiac reprogramming.
were fixed and stained with cTnT antibody. Data are mean ± SD. Scale bars, 10sion of pluripotency genes such as Nanog and Rex1 remained
nearly undetectable during the whole process (Figures 4D
and 4E). In contrast, cardiac markers, including Gata4, Tnnt2,
Myh6, and Ryr2, were gradually induced (Figure 4F).
In addition, if generation of pluripotent intermediates were crit-
ical, then using iPSC reprogramming medium with LIF for the
initiation stage (first 15 days) would yield more beating clusters.
However, this substitution resulted in a 10-fold decrease in
beating cluster number (Figure 4G). This result indicates that
the iPSC reprogramming condition is detrimental to Oct4-
induced cardiac reprogramming. All data collectively indicate
that the conversion to cardiac cells occurred at a very early
time point, far before the reprogramming to pluripotent state,
and PSC-like cells were not generated during such early stage.
DISCUSSION
Our results provide a proof-of-principle demonstration that
effective cardiac reprogramming can be achieved from fibro-
blast cells using a single genetic factor enabled by small mole-
cules. Compared with mouse cardiac reprogramming using
multiple (e.g., three or four) cardiac-specific TFs (Ieda et al.,
2010; Qian et al., 2012; Song et al., 2012), our method appears
to generate spontaneously contracting cardiomyocytes in an
accelerated fashion by passing through a cardiac mesoderm
progenitor stage. Such a stage could be further exploited for
the expansion of cardiac precursor cells for various applications
in which large numbers of characterized cardiac cells are
required.
Although ectopic Oct4 expression was still needed for car-
diac reprogramming under the current condition, the endoge-
nous pluripotency circuitry, consisting of Oct4, Nanog, and
Rex1, remains silenced. In addition, consistent with previous
findings (Efe et al., 2011; Kim et al., 2011; Li et al., 2013,
2014; Zhu et al., 2014), conditions specifically favoring estab-
lishment of pluripotency dramatically inhibited cardiac reprog-
ramming during this process. Although it remains elusive
whether rare cells could transiently (shorter than hours) express
certain pluripotency-associated genes, the data collectively
support the notion that our cardiac reprogramming process
passes through a cardiac precursor stage but does not enter
a typical/stable pluripotent state. Because our paradigm does
not produce pluripotent stem cells and reduces the culture
time required to obtain cardiac cells, our approach is also faster
and potentially safer than methods that have iPSCs as an inter-
mediate step.
In addition, the generation of functional cardiomyocytes, most
of which exhibit a ventricular subtype as characterized bymarkerac Precursor Stage
T–PCR. ‘‘H’’ represents a positive control using mRNA from embryonic heart at
.
le cell differentiationmedium (C and E) or endothelial cell differentiationmedium
muscle actin (SMA) and calponin 2 antibodies (C) or CD31 and VE-cadherin
ative PCR. Data are mean ± SD (E and F).
At day 18, live-cell images were taken to show GFP signal. (G) At day 35, cells
0 mm.
Cell Reports 6, 951–960, March 13, 2014 ª2014 The Authors 957
Figure 4. Pluripotent Cells Were Not Generated during Direct Cardiac Reprogramming by SCPF/Oct4
(A) Time-lapse imaging by phase contrast (top) and fluorescence microscopy (bottom) of induced cardiac colony formation in Oct4-GFP reporter (OG2) MEFs at
the indicated days during reprogramming. The area of spontaneous contraction was encircled (see Movie S2).
(B) At day 25, cells were fixed and immunostained with cTnT antibody. Nuclei were stained with DAPI.
(legend continued on next page)
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expression and electrophysiological analyses, will be of great
interest for both regenerative medicine and drug discovery.
Although these findings highlight the feasibility of using small
molecules to precisely specify cell fate within a particular cell
lineage, mechanistic dissection of the underlying signaling and
epigenetic pathways will require further investigation.
Similarly, the precise mechanisms underlying the synergism in
cardiac reprogramming induced by combined exposure to SCPF
andOct4 remain to be determined. It is tempting to postulate that
TGF-b signaling inhibition by SB431542 may play a role in desta-
bilizing the fibroblast phenotype (e.g., promoting mesenchymal
to epithelial transition) and blocking endoderm induction (Cham-
bers et al., 2009; Li et al., 2010; Lin et al., 2009). Wnt signaling
activation by CHIR99021 may promote initial reprogramming (Li
et al., 2009) and cardiac mesoderm induction (Lian et al., 2012).
In addition, as shown in Figure S4, we foundWnt3a has an effect
similar to CHIR99021. Importantly, XAV939, which selectively
blocks Wnt/b-catenin-mediated transcription through tankyr-
ase1/2 inhibition, strongly blocked the cardiac enhancing effect
of CHIR99021, suggesting CHIR99021’s effect is mainly
dependent on Wnt signaling downstream activity. Furthermore,
increased H3K4 methylation by parnate may enhance initial
epigenetic activation of the fibroblasts (Li et al., 2009), and for-
skolin, which activates adenylate cyclase to increase intracellular
cyclic AMP levels (Hanna et al., 2010), may further enhance car-
diac reprogramming through downstream chromatin-remodel-
ing mechanisms. Future mechanistic investigations will yield
greater insight into the role of these signaling pathways and
perhaps identify other targets for small-molecule intervention
that further enhance cardiac reprogramming efficiency.
EXPERIMENTAL PROCEDURES
Cardiac Reprogramming
MEFs and TTFs were originally passaged onto gelatin-coated tissue culture
plates. Cells were incubated with lentivirus for 12 hr and then cultured in
MEF-growth medium. After 3–5 days of recovery, cells were replated onto
Matrigel-coated (BD Biosciences) plates at 5,000 cells per cm2. The next
day, infected MEFs were switched to cardiac reprogramming media (CRM)
containing knockout Dulbecco’s modified Eagle’s medium-coated with 5%
knockout serum replacement, 15% embryonic stem cell-qualified fetal
bovine serum, 1% Glutamax, 1% nonessential amino acids, and 0.1 mM
b-mercaptoethanol, with or without small molecules. For TetO-OKS-induced
cardiac reprogramming, 2 mg/ml Dox was also added to CRM for 6 days
and then the culture medium was changed to chemical defined medium
(CDM) containing RPMI-1640 supplemented with 0.53 N2 supplement, 13
B27 supplement (without vitamin A), 0.05% BSA fraction V, 0.5% Glutamax,
and 0.1 mM b-mercaptoethanol (all from Invitrogen). A total of 20 ng/ ml of
BMP4 (Stemgent) was added to CDM for the first 5 days. For Oct4-induced
cardiac reprogramming, cells were replated at a ratio of 1:6 at day 8 and
kept cultured in CRM with small molecules until day 15, then switched to
CDM and treated with BMP4 for the first 5 days. All mouse work was done
with the approval of the University of California, San Francisco animal care
oversight committee. All small molecules were added to cells during culture
in CRM. The following small molecules were used in this study: 2 mM
SB431542, 10 mM CHIR99021, 2 mM parnate, and 10 mM forskolin.(C) Robust early activation of Oct4-GFP with OKSM transduction at day 6 using
(D–F) Time-course qRT-PCR analysis of pluripotency markers, Nanog (C) and Re
(G) Either cardiac reprogramming medium (CRM) or standard iPSC reprogramm
clusters and GFP+ colonies were counted at day 30. Data are mean ± SD.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, one table, and twomovies and can be foundwith this article online
at http://dx.doi.org/10.1016/j.celrep.2014.01.038.
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